Skip to content
LinkedIn
Twitter
Toggle Navigation
Home
People
About Us
Management Team
Board of Directors
Scientific Advisory Board
Contact
Patients
Expanded Access Policy
Pipeline
Our Pipeline
Clinical Development
Mechanism of Action
Publications
Careers
Media
In The News
Press Releases
Toggle Navigation
Home
People
About Us
Management Team
Board of Directors
Scientific Advisory Board
Contact
Patients
Expanded Access Policy
Pipeline
Our Pipeline
Clinical Development
Mechanism of Action
Publications
Careers
Media
In The News
Press Releases
ALZ-801 Development
alzheon
2025-04-08T11:28:35-04:00
Phase 3 study evaluated efficacy of valiltramiprosate in APOE4/4 Early AD subjects
Valiltramiprosate Phase 3 trial in APOE4/4 patients with Early AD
APOLLOE4 pivotal trial enrolled 325 subjects
Valiltramiprosate development history
*Active metabolite of valiltramiprosate, licensed by Alzheon from Bellus Health/Neurochem in 2013; Orange relates to study start date
Page load link
Go to Top